(3,5-Dimethylimidazol-4-yl)methanamine | 1083402-24-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (3,5-Dimethylimidazol-4-yl)methanamine
• CAS: 1083402-24-7
• 化学式: C₆H₁₁N₃
• mdl: MFCD08703648
• 分子量: 125.173
• InChiKey: NNARKMQXUKUQFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-butyl-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-1H-pyrazole-4-carboxylic acid 、 (3,5-Dimethylimidazol-4-yl)methanamine 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 5-butyl-N-[(1,4-dimethyl-1H-imidazol-5-yl)methyl]-1-[5-methyl-4-(2-thienyl)pyrimidin-2-yl]-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes

  摘要：

  GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic beta-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.

  DOI：

  10.1021/ml400186z

文献信息

• Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes
  作者：Narihiro Toda、Xiaolin Hao、Yasuyuki Ogawa、Kozo Oda、Ming Yu、Zice Fu、Yi Chen、Yongjae Kim、Mike Lizarzaburu、Sarah Lively、Shauna Lawlis、Michiko Murakoshi、Futoshi Nara、Nobuaki Watanabe、Jeff D. Reagan、Hui Tian、Angela Fu、Alykhan Motani、Qingxiang Liu、Yi-Jyun Lin、Run Zhuang、Yumei Xiong、Peter Fan、Julio Medina、Leping Li、Masanori Izumi、Ryo Okuyama、Satoshi Shibuya

  DOI：10.1021/ml400186z

  日期：2013.8.8

  GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic beta-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.